The role of platelets in the pathogenesis of systemic sclerosis

Frontiers in Immunology

Volumn 3, Issue JUN, 2012, Pages

  Ramirez, Giuseppe A ^a   Franchini, Stefano ^a   Rovere Querini, Patrizia ^a   Sabbadini, Maria Grazia ^a   Manfredi, Angelo A ^a   Maugeri, Norma ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Autoimmunity; Collagen; Hmgb1; Inflammation; Platelets; Serotonin; Systemic sclerosis; Vascular injury

Indexed keywords

EID: 84874165398     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00160     Document Type: Review

References (64)

1. Agache, I., Radoi, M., and Duca, L. (2007). Platelet activation in patients with systemic scleroderma-pattern and significance. Rom. J. Intern. Med. 45, 183-191.
2. Austrup, F., Vestweber, D., Borges, E., Lohning, M., Brauer, R., Herz, U., Renz, H., Hallmann, R., Scheffold, A., Radbruch, A., and Hamann, A. (1997). Pand E-selectin mediate recruitment of T-helper-1 but not Thelper-2 cells into inflammed tissues. Nature 385, 81-83.
3. Banchereau, J., and Pascual, V. (2006). Type I interferon in systemiclupuserythematosusandother autoimmune diseases. Immunity 25, 383-392.
4. Belch, J. J., O'Dowd, A., Forbes, C. D., and Sturrock, R. D. (1985). Platelet sensitivity to a prostacyclin analogue insystemicsclerosis.Br.J.Rheumatol. 24, 346-350.
5. Biondi, M. L., Marasini, B., Bianchi, E., and Agostoni, A. (1988). Plasma free andintraplateletserotonininpatients with Raynaud's phenomenon. Int. J. Cardiol. 19, 335-339.
6. Bottazzi, B., Doni, A., Garlanda, C., and Mantovani, A. (2010). An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 28, 157-183.
7. Candela, M., Pansoni, A., Jannino, L., Menditto, V. G., Natalini, M., Ravaglia, F., Da Lio, L., Scorza, R., Gabrielli, A., and Danieli, G. (2001). Coagulativemodificationsinpatients with systemic sclerosis treated with iloprostornifedipine. Ann. Ital. Med. Int. 16, 170-174.
8. Chiang, T. M., Takayama, H., and Postlethwaite, A. E. (2006). Increase in platelet non-integrin type I collagen receptor in patients with systemic sclerosis. Thromb. Res. 117, 299-306.
9. Clark, S. R., Ma, A. C., Tavener, S. A., McDonald, B., Goodarzi, Z., Kelly, M. M., Patel, K. D., Chakrabarti, S., McAvoy, E., Sinclair, G. D., Keys, E. M., Allen-Vercoe, E., Devinney, R., Doig, C.J., Green, F.H., and Kubes, P. (2007). Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteriainsepticblood.Nat.Med.13, 463-469.
10. Coleiro, B., Marshall, S. E., Denton, C. P., Howell, K., Blann, A., Welsh, K. I., and Black, C. M. (2001). Treatment of Raynaud's phenomenon with the selectiveserotoninreuptakeinhibitor fluoxetine. Rheumatology (Oxford) 40, 1038-1043.
11. D'Angelo, W. A., Fries, J. F., Masi, A. T., and Shulman, L. E. (1969). Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fiftyeight matched controls. Am. J. Med. 46, 428-440.
12. Dees, C., Akhmetshina, A., Zerr, P., Reich, N., Palumbo, K., Horn, A., Jungel, A., Beyer, C., Kronke, G., Zwerina, J., Reiter, R., Alenina, N., Maroteaux, L., Gay, S., Schett, G., Distler, O., and Distler, J. H. (2011). Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 208, 961-972.
13. Diacovo, T. G., Catalina, M. D., Siegelman, M. H., and von Andrian, U. H. (1998). Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficientmice.J.Exp.Med. 187, 197-204.
14. Diacovo, T. G., Puri, K. D., Warnock, R. A., Springer, T. A., and von Andrian, U. H. (1996). Platelet-mediated lymphocyte delivery to high endothelial venules. Science 273, 252-255.
15. Donners, M.M., Beckers, L., Lievens, D., Munnix, I., Heemskerk, J., Janssen, B. J., Wijnands, E., Cleutjens, J., Zernecke, A., Weber, C., Ahonen, C. L., Benbow, U., Newby, A. C., Noelle, R. J., Daemen, M. J., and Lutgens, E. (2008). The CD40-TRAF6 axis is thekeyregulatoroftheCD40/CD40L system in neointima formation and arterialremodeling.Blood 111, 4596- 4604.
16. Fontana, V., Horstman, L.L., Donna, E., Dudkiewicz, P., Ahn, E. R., and Ahn, Y. S. (2007). Interstitial lung disease (ILD)andsevereITP.Hematology 12, 75-80.
17. Freedman, R. R., Girgis, R., and Mayes, M.D. (1999).Endothelialand adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J. Rheumatol. 26, 2386-2388.
18. Frid, M. G., Kale, V. A., and Stenmark, K. R. (2002). Mature vascular endothelium can give rise to smooth muscle cells via endothelial- mesenchymal transdifferentiation: in vitro analysis. Circ. Res. 90, 1189- 1196.
19. Friedhoff, L. T., Seibold, J. R., Kim, H. C., and Simester, K. S. (1984). Serotonin induced platelet aggregation in systemic sclerosis. Clin. Exp. Rheumatol. 2, 119-123.
20. Garcia-Porrua, C., Margarinos, C. C., and Gonzalez-Gay, M. A. (2004). Raynaud's phenomenon and serotoninreuptakeinhibitors.J.Rheumatol.31, 2090;authorreply2090-2091.
21. Gardner, H., Shearstone, J. R., Bandaru, R., Crowell, T., Lynes, M., Trojanowska, M., Pannu, J., Smith, E., Jablonska, S., Blaszczyk, M., Tan, F. K., and Mayes, M. D. (2006). Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts.ArthritisRheum.54, 1961-1973.
22. Giusti, B., Fibbi, G., Margheri, F., Serrati, S., Rossi, L., Poggi, F., Lapini, I., Magi, A., Del Rosso, A., Cinelli, M., Guiducci, S., Kahaleh, B., Bazzichi, L., Bombardieri, S., Matucci-Cerinic, M., Gensini, G. F., Del Rosso, M., and Abbate, R. (2006). A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res. Ther. 8, R115.
23. Goodfield, M. J., Orchard, M. A., and Rowell, N. R. (1988). Increased platelet sensitivity to collageninduced aggregation in whole blood patients with systemic sclerosis. Clin. Exp. Rheumatol. 6, 285-288.
24. Goodfield, M. J., Orchard, M. A., and Rowell, N. R. (1993). Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br. J. Haematol. 84, 675-680.
25. Harris, H. E., Andersson, U., and Pisetsky, D. S. (2012). HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8, 195-202.
26. Herrick, A. L. (2011). Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr. Opin. Rheumatol. 23, 555-561.
27. Holt, C. M., Lindsey, N., Moult, J., Malia, R. G., Greaves, M., Hume, A., Rowell, N. R., and Hughes, P. (1989). Antibodydependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin. Exp. Immunol. 78, 359-365.
28. Iannacone, M., Sitia, G., Isogawa, M., Marchese, P., Castro, M. G., Lowenstein, P. R., Chisari, F. V., Ruggeri, Z. M., and Guidotti, L. G. (2005). Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat. Med. 11, 1167-1169.
29. Kahaleh, M. B., and Fan, P. S. (1997). Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin. Immunol. Immunopathol. 83, 32-40.
30. Kahaleh, M. B., and LeRoy, E. C. (1999). Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31, 195-214.
31. Kahaleh, M. B., Osborn, I., and Leroy, E. C. (1982). Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann. Intern. Med. 96, 610-613.
32. Klimiuk, P. S., Grennan, A., Weinkove, C., and Jayson, M. I. (1989). Platelet serotonin in systemic sclerosis. Ann. Rheum. Dis. 48, 586-589.
33. Kosaki, G. (2005). In vivo platelet production from mature megakaryocytes: does platelet release occur via proplatelets? Int. J. Hematol. 81, 208-219.
34. Kowal-Bielecka, O., Kowal, K., Lewszuk, A., Bodzenta-Lukaszyk, A., Walecki, J., and Sierakowski, S. (2005). Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann. Rheum. Dis. 64, 484-486.
35. Kuwana, M., Okazaki, Y., Yasuoka, H., Kawakami, Y., and Ikeda, Y. (2004). Defective vasculogenesis in systemic sclerosis. Lancet 364, 603-610.
36. Lafyatis, R., andYork, M. (2009). Innate immunity and inflammation in systemic sclerosis. Curr. Opin. Rheumatol. 21, 617-622.
37. Luchetti, M. M., Sambo, P., Majlingova, P., Svegliati Baroni, S., Peri, G., Paroncini, P., Introna, M., Stoppacciaro, A., Mantovani, A., and Gabrielli, A. (2004). Scleroderma fibroblasts constitutively express the long pentraxin PTX3. Clin. Exp. Rheumatol. 22(Suppl. 33), S66-S72.
38. Ludwig, R. J., Bergmann, P., Garbaraviciene, J., von Stebut, E., Radeke, H. H., Gille, J., Diehl, S., Hardt, K., Henschler, R., Kaufmann, R., Pfeilschifter, J. M., and Boehncke, W. H. (2010). Platelet, not endothelial, P-selectin expression contributes to generation of immunity in cutaneous contact hypersensitivity. Am. J. Pathol. 176, 1339-1345.
39. Manfredi, A. A., Rovere-Querini, P., Bottazzi, B., Garlanda, C., and Mantovani, A. (2008). Pentraxins, humoral innate immunity and tissue injury. Curr. Opin. Immunol. 20, 538-544.
40. Manfredi, A.A., Rovere-Querini, P., and Maugeri, N. (2010). Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr. Opin. Hematol. 17, 3-8.
41. Mannucci, P. M., Lombardi, R., Lattuada, A., Perticucci, E., Valsecchi, R., and Remuzzi, G. (1989). SupranormalvonWillebrandfactormultimers inscleroderma. Blood 73, 1586-1591.
42. Margheri, F., Serrati, S., Lapucci, A., Chilla, A., Bazzichi, L., Bombardieri, S., Kahaleh, B., Calorini, L., Bianchini, F., Fibbi, G., and Del Rosso, M. (2010). Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. Arthritis Rheum. 62, 2488-2498.
43. Martinez de la Torre, Y., Fabbri, M., Jaillon, S., Bastone, A., Nebuloni, M., Vecchi, A., Mantovani, A., and Garlanda, C. (2010). Evolution of the pentraxin family: the new entry PTX4. J. Immunol. 184, 5055-5064.
44. Maugeri, N., Baldini, M., Ramirez, G. A., Rovere-Querini, P., and Manfredi, A. A. (2012). Platelet- leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thromb. Res. 129, 267-273.
45. Maugeri, N., Rovere-Querini, P., Baldini, M., Sabbadini, M. G., and Manfredi, A. A. (2009). Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin. Exp. Immunol. 156, 395-404.
46. Mauviel, A. (2005). Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol. Med. 117, 69-80.
47. May, A. E., Kalsch, T., Massberg, S., Herouy, Y., Schmidt, R., and Gawaz, M. (2002). Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 106, 2111-2117.
48. Miller, K., Dresner, I. G., and Michael, A. F. (1980). Localization of platelet antigens in human kidney disease. Kidney Int. 18, 472-479.
49. Mullenix, P. S., Andersen, C. A., and Starnes, B. W. (2005). Atherosclerosis as inflammation. Ann. Vasc. Surg. 19, 130-138.
50. Nurden, A. T. (2011). Platelets, inflammation and tissue regeneration. Thromb. Haemost. 105(Suppl. 1), S13-S33.
51. Palaniswamy, C., Frishman, W. H., and Aronow, W. S. (2012). Carcinoid heart disease. Cardiol. Rev.
52. Pattanaik, D., Brown, M., and Postlethwaite, A. E. (2011). Vascular involvement in systemic sclerosis (scleroderma). J. Inflamm. Res. 4, 105-125.
53. Postlethwaite, A. E., and Chiang, T. M. (2007). Platelet contributions to thepathogenesisofsystemicsclerosis. Curr. Opin. Rheumatol. 19, 574-579.
54. Semple, J. W., Italiano, J. E. Jr., and Freedman, J. (2011). Platelets and the immune continuum. Nat. Rev. Immunol. 11, 264-274.
55. Silveri, F., De Angelis, R., Poggi, A., Muti, S., Bonapace, G., Argentati, F., and Cervini, C. (2001). Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand. J. Rheumatol. 30, 290-296.
56. Solanilla, A., Villeneuve, J., Auguste, P., Hugues, M., Alioum, A., Lepreux, S., Ducroix, J. P., Duhaut, P., Conri, C., Viallard, J.F., Nurden, A.T., Constans, J., and Ripoche, J. (2009). The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 48, 1036-1044.
57. Steen, V. D., and Medsger, T. A. (2007). Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 66, 940-944.
58. Trojanowska, M. (2008). Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 47(Suppl. 5), v2-v4.
59. Trostle, D. C., Bedetti, C. D., Steen, V. D., Al-Sabbagh, M. R., Zee, B., and Medsger, T. A. Jr. (1988). Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum. 31, 393-400.
60. Tuder, R.M., Cool, C.D., Geraci, M.W., Wang, J., Abman, S. H., Wright, L., Badesch, D., andVoelkel, N.F.(1999). Prostacyclin synthase expression is decreasedinlungsfrompatientswith severe pulmonary hypertension. Am. J. Respir. Crit. Care. Med. 159, 1925-1932.
61. Verschoor, A., Neuenhahn, M., Navarini, A. A., Graef, P., Plaumann, A., Seidlmeier, A., Nieswandt, B., Massberg, S., Zinkernagel, R. M., Hengartner, H., and Busch, D. H. (2011). A platelet-mediated system for shuttling blood-borne bacteria to CD8alpha+ dendritic cells depends on glycoprotein GPIb and complement C3. Nat. Immunol. 12, 1194-1201.
62. Whitfield, M. L., Finlay, D. R., Murray, J. I., Troyanskaya, O. G., Chi, J. T., Pergamenschikov, A., McCalmont, T. H., Brown, P. O., Botstein, D., and Connolly, M.K.(2003).Systemicand celltype-specificgeneexpressionpatterns in scleroderma skin. Proc. Natl. Acad. Sci. U.S.A. 100, 12319-12324.
63. Yeaman, M. R. (2010). Platelets in defense against bacterial pathogens. Cell.Mol.LifeSci.67, 525-544.
64. Yoshizaki, A., Komura, K., Iwata, Y., Ogawa, F., Hara, T., Muroi, E., Takenaka, M., Shimizu, K., Hasegawa, M., Fujimoto, M., and Sato, S. (2009).Clinicalsignificanceof serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J. Clin. Immunol. 29, 180-189.